Currently, malignant tumors have become one of the leading causes of human death, and the incidence rate is increasing year by year. According to the “Global Cancer Facts and Figures 2007” released by the American Cancer Society (ACS), a total of 7.6 million people died of cancer worldwide in 2007 (about 20,000 cancer deaths per day), and the number of new cases exceeded 12 million, and the number of new patients is expected to reach 15 million per year in 2020, with the total number of cancers increasing by 73% in developing countries and 29% in developed countries. percent. Malignant tumors are a serious threat to human health. In the past half century, the treatment of tumors has entered the era of comprehensive treatment. Individualized and comprehensive treatment guided by evidence-based medicine is the standard of care today. Although the existing treatment paradigm has solved some of the problems and there have been many first signs and good trends and some improvement in cure rates, there is still a need for improvement in terms of overall strategies. Approximately 30% of patients do not respond to treatment, and 30% of patients experience recurrence and metastasis after treatment. Therefore, the search for new treatment options, pathways and tools is an urgent need in clinical oncology therapeutics. Modern medicine (surgery, radiotherapy, chemotherapy, biologic targeted therapy) is the main means of tumor treatment, while TCM is an important auxiliary means, which has a role in the comprehensive treatment of tumors by emphasizing holistic thinking and grasping the nature of the disease in general. As TCM oncology workers should fully inherit, master and apply modern tumor therapeutic methods, follow the latest clinical research results of modern clinical oncology and practice under the guidance of evidence-based medicine. At the same time, we should strive to discover the weak points under today’s standardized treatment and integrate TCM scientifically under the guidance of TCM theory, and be brave to explore and explore new treatment options, so as to achieve therapeutic effects that are both superior to TCM and beyond Western medicine. This may be the best treatment modality in China at present. For example, the combination of TCM with surgery, radiotherapy, chemotherapy and biological therapy, the application of TCM for palliative treatment of advanced cancer, etc., targeting the blind spots and weaknesses of modern medicine for tumor treatment as the entry point of TCM, with the goal of improving clinical efficacy, improving patients’ quality of life and prolonging survival. However, we should not hastily “replace” modern medicine for tumor treatment, we should have reasons to fully enjoy the achievements of Chinese medicine for tumor treatment. In recent years, Chinese medicine has played an important role in the comprehensive treatment of tumors, mainly in the following aspects: Chinese medicine can prevent and treat the toxic side effects of radiotherapy and chemotherapy; Chinese medicine has synergistic effects with western medicine (to improve the recent and long-term efficacy of tumor treatment); Chinese medicine can improve the symptoms of patients to a certain extent through evidence-based treatment and can improve the immune function of the body. However, there are certain misunderstandings on how to combine with modern tumor treatment for a long time. Through nearly 30 years of clinical exploration, we have learned that the diagnosis and treatment of tumor patients can be roughly divided into four stages: perioperative stage, adjuvant radiotherapy and chemotherapy stage, follow-up and observation stage and late palliative treatment stage, and the role of Chinese medicine in these different stages is different. In the past research on TCM treatment of tumors, generally, tumors were treated as a single, homogeneous disease for overall evidence-based treatment, and several types of evidence were formulated with corresponding prescriptions in combination with literature and expert experience. The shortcoming is that it ignores the heterogeneity of TCM symptoms in different stages of the disease. In fact, tumor is a qualitatively different process from occurrence, development, evolution to fate, and it has four different stages: perioperative, adjuvant, follow-up and palliative. In the perioperative period, due to factors such as anesthesia, surgery and psychological trauma, it is very easy to cause the characteristics of qi stagnation and qi deficiency in patients; in the adjuvant treatment period, due to modern treatments such as radiotherapy and chemotherapy, it can obviously affect the natural state of Chinese medicine evidence of patients. We observed the effect of chemotherapy on the TCM symptoms of tumor patients and proved that chemotherapeutic drugs can significantly aggravate or cause the patient’s spleen deficiency symptoms (spleen qi deficiency); this was confirmed in our animal experiments and several clinical intervention studies. Radiotherapy, especially to the head, neck and chest, can be injurious as a heat evil. These modern treatments have not fully revealed the law of influence on the TCM evidence, which brings greater blindness to the TCM treatment. Due to the different physical constitution of patients (Wang Qi’s theory of nine bodies), the evidence situation of patients in the follow-up period is more complicated, which requires us to identify the physical constitution and evidence (correct application of body identification and evidence-based treatment), to determine the treatment period, to prevent tumor recurrence and metastasis as the target, and to clarify the target population (the beneficiary population), and we observe that the more common evidence types are qi deficiency and phlegm obstruction and yin deficiency and internal heat. The patients in the palliative phase are those who receive palliative radiotherapy or chemotherapy at PS 0-2 and those who receive BSC (best supportive care) at PS > 2. Therefore, the TCM evidence is more complicated and its regularity should be determined through clinical studies. We observed that the more common types of evidence are qi stagnation and blood stasis, liver and kidney yin deficiency, etc. It can be seen that there are obvious differences in the TCM symptoms of the four stages of tumor, and there is a great need to establish a clinical study. Based on the above understanding, how to find the entry point for tumor TCM application? Our experience is to start from the blind spot and weak point of modern tumor treatment. Modern medicine generally adopts the means of observation rather than treatment for tumor patients in the follow-up period, and the recurrence rate of tumor at this stage can reach 50-70%, which is the “blind spot” in the treatment process of modern medicine. Chinese medicine has more room to play in this area, through body regulation and evidence-based treatment, it can improve the internal environment of patients and increase the resistance, which can reduce the recurrence and metastasis of tumor. Toxic side effects of radiotherapy and chemotherapy affect the rate of passing treatment, and complications (such as cancer fever, cancer pain, bone-related events, cachexia, etc.) in advanced stage patients are two weaknesses of modern medical tumor treatment. Chinese medicine has been relatively more researched in this field in the past. Taking “1 blind spot and 2 weak spots” as the entry point of TCM tumor treatment, we should also pay attention to the use of “two integrations”, namely: the integration of TCM and Western medicine, and the integration of TCM tonics, Chinese patent medicines and intravenous Chinese medicine preparations. Because TCM is still an important adjuvant for tumor treatment. In this regard, we propose that TCM tumor treatment should follow the new concept of “four stages, one blind area and two weak points”. In four different stages, TCM should adopt different strategies and focus on different purposes and meanings: to improve the patient’s tolerance to surgery, to promote post-operative recovery, to regulate immune function and to pave the way for subsequent treatment; to increase sensitivity to radiation and chemotherapy and to reduce toxicity. The application of Chinese medicine should be determined through clinical research. First of all, tumor treatment should follow the frontier of the discipline and study the characteristics and rules of TCM evidence of modern tumor four-stage process under the guidance of TCM theory, and study the influence of modern treatment on TCM evidence. Based on the evidence research, precise interventional treatment should be carried out to translate the improvement of evidence into survival advantage (both translational research). Our viewpoint: to control tumors by means of modern medicine, and to adjust the growth environment of tumors, i.e., the carrier of tumor growth, by using TCM, i.e., to take the blind spot and weak point of modern medicine for tumor treatment as a good entry point for TCM. Under the guidance of this academic idea, we use evidence-based medicine as a tool to formulate the TCM treatment pathway for tumors and to develop TCM treatment standards and efficacy criteria for tumors to improve the efficacy. The research should be conducted around the “evidence”, especially the in-depth research on the characteristics of tumor evidence types, in order to make a breakthrough in the “evidence”. Based on the development of strict and recognized criteria of evidence, scientific and comparable characteristics of evidence patterns can be obtained. On the basis of the research on the evidence, with the goal of improving clinical efficacy and the characteristics of randomized, open, multicenter and large-scale collaboration, we organize scientific research units with many years of experience in combining Chinese and Western medicine with tumor treatment to conduct large-scale collaborative research in order to establish and continuously improve clinical treatment protocols for tumors combining Chinese and Western medicine. Overall survival (OS) is the gold standard and the main goal, and quality of survival, tumor-free survival, and progression to disease are all important secondary goals of treatment. Through clinical research, especially the translational research on the improvement of symptoms and endpoint events, we should clarify the core symptoms, main symptoms, secondary symptoms and concomitant diseases in each stage of the disease, so as to enrich the connotation of TCM tumors and make clinical treatment more targeted.